BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mauro MJ. Lifelong TKI therapy: how to manage cardiovascular and other risks. Hematology Am Soc Hematol Educ Program 2021;2021:113-21. [PMID: 34889360 DOI: 10.1182/hematology.2021000239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Mehra N, Varmeziar A, Chen X, Kronick O, Fisher R, Kota V, Mitchell CS. Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Cancers 2022;14:4686. [DOI: 10.3390/cancers14194686] [Reference Citation Analysis]
2 Upshaw JN, Travers R, Jaffe IZ. ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity. JACC: CardioOncology 2022;4:384-386. [DOI: 10.1016/j.jaccao.2022.07.001] [Reference Citation Analysis]
3 Parrella A, Iannuzzi A, Annunziata M, Covetti G, Cavallaro R, Aliberti E, Tortori E, Iannuzzo G. Haematological Drugs Affecting Lipid Metabolism and Vascular Health. Biomedicines 2022;10:1935. [DOI: 10.3390/biomedicines10081935] [Reference Citation Analysis]
4 Lipton JH, Brümmendorf TH, Gambacorti-passerini C, Garcia-gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]